Hypertrophic osteodystrophy

Verify with FDA CVM →

VeDDRA Code: 2124

17 adverse event reports referencing this reaction

17
Total Reports
2
Deaths
1180.0%
Death Rate

Species Most Affected

Dog 17

Breeds Most Affected

Weimaraner 3
Retriever - Labrador 2
Shepherd Dog - German 2
Crossbred Canine/dog 2
Deutsche Dogge, Great Dane 2
Great Pyrenees 1
Pointer (unspecified) 1
Retriever (unspecified) 1
Cattle Dog - Flanders (Bouvier) 1
Poodle (unspecified) 1

Associated Drugs

Canine Adenovirus Type 2, Strain Manhattan, 12-13-76; Canine Distemper Virus, St 5
Milbemycin Oxime + Spinosad 4
Maropitant Citrate 3
Pyrantel Pamoate (Pyrantel Embonate) 2
Selamectin 2
Ampicillin Trihydrate 2
Metronidazole 2
Robenacoxib 2
Afoxolaner 2
Milbemycin Oxime + Praziquantel 2
Pyrantel Pamoate;Sarolaner 2
Spinosad 1
Ivermectin + Pyrantel Pamoate + Praziquantel 1
Ivermectin 1
Amoxicillin Trihydrate; Clavulanate Potassium ( K-Clavulanate) 1
Dapp 1
Bordetella Bronchiseptica Vaccine 1
Canine Coronavirus, Strain Nl-18, Ms-P40 Lot #1, 9-29-82 1
Amoxicillin 1
Oclacitinib Maleate 1

Data Summary

Metric Value
Total reports referencing reaction 17
Reports with fatal outcome 2
Case-fatality rate (reported events) 1180.0%
Species observed 1
Breeds observed 11
Drugs associated with reaction 20

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER); reaction term coded under VeDDRA 2124.

Hypertrophic osteodystrophy Reaction Insights

The FDA Center for Veterinary Medicine database currently lists 17 adverse event reports that reference Hypertrophic osteodystrophy as a reaction term, including 2 reports with a death outcome — a 1180.0% case-fatality figure calculated across only those events where this reaction was coded. The reaction is indexed in the openFDA system under VeDDRA code 2124, the standardized veterinary dictionary used to normalize clinical signs across submitters. Because reports are voluntary and often describe multiple concurrent signs per animal, the volume here reflects reporting intensity rather than true incidence in the broader pet population.

Hypertrophic osteodystrophy appears most frequently in reports for Dog (17 reports) — with Dog dominating at 17 entries. Within those species, the breeds most often named alongside this reaction are Weimaraner (3), Retriever - Labrador (2), Shepherd Dog - German (2). These distributions are influenced both by underlying breed popularity and by how veterinarians and owners code a given clinical sign, so they should be interpreted as a reporting fingerprint rather than a pure susceptibility ranking.

The drugs most commonly co-reported with Hypertrophic osteodystrophy are Canine Adenovirus Type 2, Strain Manhattan, 12-13-76; Canine Distemper Virus, St (5 reports), Milbemycin Oxime + Spinosad (4 reports), Maropitant Citrate (3 reports), Pyrantel Pamoate (Pyrantel Embonate) (2 reports), with Canine Adenovirus Type 2, Strain Manhattan, 12-13-76; Canine Distemper Virus, St appearing alongside this reaction in 5 submissions. Co-reporting does not establish that any specific product caused the reaction — FDA CVM data captures temporal association only. The value of these aggregates is in flagging which therapeutic classes appear repeatedly alongside a given clinical sign, so owners and veterinarians can ask targeted questions about medications currently in use.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial